<DOC>
	<DOCNO>NCT00124579</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Biological therapy , thalidomide , may stimulate immune system different way stop cancer cell grow . It may also stop growth cancer block blood flow cancer . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib together thalidomide dexamethasone may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together thalidomide dexamethasone work treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>S0417 Bortezomib , Thalidomide , Dexamethasone Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine confirm overall response rate ( complete remission , remission , partial remission ) patient relapse refractory multiple myeloma treat bortezomib , thalidomide , dexamethasone . - Determine overall progression-free survival patient treat regimen . - Determine qualitative quantitative toxic effect regimen patient . - Correlate , preliminarily , treatment bortezomib activation osteoblasts patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive bortezomib IV day 1 , 4 , 8 , 11 , oral thalidomide daily day 1-21 , oral dexamethasone daily day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 . Treatment repeat every 21 day achievement confirm complete remission ( CR ) , remission ( R ) , partial remission ( PR ) OR 8 course absence disease progression unacceptable toxicity . Patients achieve confirmed CR , R , PR reach plateau prior receive maximum 8 course induction therapy OR achieve confirm CR , R , PR receive maximum 8 course induction therapy proceed maintenance therapy . Patients achieve stable disease receive maximum 8 course induction therapy either proceed maintenance therapy receive treatment bortezomib , thalidomide , dexamethasone off-study . - Maintenance therapy : Patients receive oral dexamethasone day 1-4 . Courses repeat every 28 day 3 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow within 30 day every 6 month 5 year . PROJECTED ACCRUAL : A total 90 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma ( MM ) Active disease Relapsed refractory disease ≥ 1 prior therapy MM , may include autologous allogeneic stem cell transplantation Relapse define occurrence follow prior treatment : Myeloma protein level increase &gt; 100 % low previously record level Myeloma protein level increase define response criterion partial remission Reappearance myeloma peak disappear prior treatment Increase size number lytic bone lesion and/or focal lesion xray , MRI , positron emission tomography , and/or CT scan Refractory disease define response ( i.e. , achieve complete remission , remission , partial remission ) prior therapy Measurable disease No evidence POEMS ( polyneuropathy , organomegaly , endocrinopathy , presence Mprotein , skin change ) syndrome Must register protocol SWOGS0334 PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 ( unless due bone pain ) Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 50,000/mm^3 Hepatic AST ALT ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ 3 time ULN Renal Creatinine clearance &gt; 30 mL/min Cardiovascular No New York Heart Association class III IV congestive heart failure No myocardial infarction within past 6 month No poorly control hypertension Other Not pregnant nursing Negative pregnancy test Fertile female patient must use effective double method contraception ≥ 4 week , , ≥ 4 week completion study treatment ( 4 week completion study treatment male patient ) No blood , ovum , sperm donation study treatment No active infection require antibiotic No neurotoxicity ≥ grade 2 No diabetes mellitus No serious medical psychiatric illness would preclude study treatment No malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy At least 14 day since prior chemotherapy ( 28 day nitrosoureas ) recover Endocrine therapy Not specify Radiotherapy At least 14 day since prior radiotherapy recover Surgery Not specify Other No prior bortezomib alone combine thalidomide Concurrent participation protocol SWOGS0309 allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>